Inge Juul Sørensen

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

Martín Rudwaleit, Désirée van der Heijde, R. B. M. Landewé et al. · Annals of the Rheumatic Diseases · 2009 · 3.6K citations · Full text

Medicine, Radiology, Musculoskeletal Medicine +11

Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients.

Mikkel Faurschou, Inge Juul Sørensen, Lene Mellemkjær et al. · PubMed · 2008 · 314 citations

Medicine, Dermatology, Oncology +13

A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

Bente Glintborg, Inge Juul Sørensen, Anne Gitte Loft et al. · Annals of the Rheumatic Diseases · 2017 · 249 citations

Medicine, Clinical Sciences, Internal Medicine +17

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

Bente Glintborg, Anne Gitte Loft, Emina Omerovic et al. · Annals of the Rheumatic Diseases · 2018 · 155 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14

Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis

Mikkel Faurschou, Lene Mellemkjær, Inge Juul Sørensen et al. · Arthritis & Rheumatism · 2009 · 146 citations

Medicine, Cardiology, Internal Medicine +14